Tyrosine-based 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine and -adenine ((S)-HPMPC and (S)-HPMPA) prodrugs: synthesis, stability, antiviral activity, and in vivo transport studies.

Eight novel single amino acid (6-11) and dipeptide (12, 13) tyrosine P-O esters of cyclic cidofovir ((S)-cHPMPC, 4) and its cyclic adenine analogue ((S)-cHPMPA, 3) were synthesized and evaluated as prodrugs. In vitro IC(50) values for the prodrugs (<0.1-50 μM) vs vaccinia, cowpox, human cytomegalovirus, and herpes simplex type 1 virus were compared to those for the parent drugs ((S)-HPMPC, 2; (S)-HPMPA, 1; IC(50) 0.3-35 μM); there was no cytoxicity with KB or HFF cells at ≤100 μM. The prodrugs exhibited a wide range of half-lives in rat intestinal homogenate at pH 6.5 (<30-1732 min) with differences of 3-10× between phostonate diastereomers. The tyrosine alkylamide derivatives of 3 and 4 were the most stable. (l)-Tyr-NH-i-Bu cHPMPA (11) was converted in rat or mouse plasma solely to two active metabolites and had significantly enhanced oral bioavailability vs parent drug 1 in a mouse model (39% vs <5%).

[1]  C. McKenna,et al.  Serine side chain-linked peptidomimetic conjugates of cyclic HPMPC and HPMPA: synthesis and interaction with hPEPT1. , 2010, Molecular pharmaceutics.

[2]  K. Hostetler.  Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art. , 2009, Antiviral research.

[3]  C. McKenna,et al.  In vitro transport, activation and antiviral evaluation of new HPMPA prodrugs synthesized on a solid support , 2009 .

[4]  C. McKenna,et al.  191New peptidomimetic prodrugs of acyclic and cyclic cidofovir: sar studies of chemical and enzymatic activation mechanisms , 2009 .

[5]  C. McKenna,et al.  Interactions Between the Human Oligopeptide Transporter, hPepT1 and Serine Side-chain-linked Cidofovir Prodrugs , 2009 .

[6]  C. McKenna,et al.  Prodrug approaches to improving the oral absorption of antiviral nucleotide analogues , 2009, Expert opinion on drug delivery.

[7]  K. Ishigami,et al.  Synthesis and Structure Revision of Tyroscherin, a Growth Inhibitor of IGF-1-Dependent Tumor Cells. , 2009 .

[8]  E. De Clercq,et al.  Antiviral agents acting as DNA or RNA chain terminators. , 2009, Handbook of experimental pharmacology.

[9]  K. Hostetler,et al.  Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models. , 2008, Antiviral research.

[10]  C. McKenna,et al.  Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity. , 2008, Molecular pharmaceutics.

[11]  Fujun Li,et al.  Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting. , 2008, Journal of pharmaceutical sciences.

[12]  P. Baran,et al.  Scope and mechanism of direct indole and pyrrole couplings adjacent to carbonyl compounds: total synthesis of acremoauxin A and oxazinin 3. , 2007, Journal of the American Chemical Society.

[13]  J. Grimm,et al.  Suppression of Racemization in the Carbonylation of Amino Acid-Derived Aryl Triflates. , 2007 .

[14]  J. Grimm,et al.  Suppression of racemization in the carbonylation of amino acid-derived aryl triflates , 2007 .

[15]  C. McKenna,et al.  Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir. , 2007, Bioorganic & medicinal chemistry letters.

[16]  E. De Clercq.  The acyclic nucleoside phosphonates from inception to clinical use: historical perspective. , 2007, Antiviral research.

[17]  E. De Clercq,et al.  Activities of Alkoxyalkyl Esters of Cidofovir (CDV), Cyclic CDV, and (S)-9-(3-Hydroxy-2-Phosphonylmethoxypropyl)Adenine against Orthopoxviruses in Cell Monolayers and in Organotypic Cultures , 2006, Antimicrobial Agents and Chemotherapy.

[18]  M. Ariza.  Current Prodrug Strategies for the Delivery of Nucleotides into Cells , 2005 .

[19]  R. Buller,et al.  Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model. , 2004, Virology.

[20]  William A. Lee,et al.  Aryl Ester Prodrugs of Cyclic HPMPC. I: Physicochemical Characterization and In Vitro Biological Stability , 1999, Pharmaceutical Research.

[21]  A. Holý.  Phosphonomethoxyalkyl analogs of nucleotides. , 2003, Current pharmaceutical design.

[22]  Martin J Scanlon,et al.  Conformationally constrained macrocycles that mimic tripeptide beta-strands in water and aprotic solvents. , 2002, Journal of the American Chemical Society.

[23]  K. Hostetler,et al.  Enhanced Inhibition of Orthopoxvirus Replication In Vitro by Alkoxyalkyl Esters of Cidofovir and Cyclic Cidofovir , 2002, Antimicrobial Agents and Chemotherapy.

[24]  H. Pelicano,et al.  Synthesis, in vitro antiviral evaluation, and stability studies of bis(S-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability. , 1996, Journal of medicinal chemistry.

[25]  T. Momose,et al.  Studies on the Novel Cyclodepsipeptides. A Total Synthesis of (+)-Jasplakinolide (Jaspamide) , 1994 .

[26]  E. De Clercq,et al.  Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine , 1993, Antimicrobial Agents and Chemotherapy.

[27]  F. Fenner.  Smallpox: emergence, global spread, and eradication. , 1993, History and philosophy of the life sciences.

[28]  R. Webb,et al.  Synthesis and Antiviral Activity of Nucleotide Analogues Bearing the ( S)-(3-Hydroxy-2-phosphonylmethoxy)propyl Moiety Attached to Adenine, Guanine, and Cytosine , 1991 .

[29]  M. Prichard,et al.  A microtiter virus yield reduction assay for the evaluation of antiviral compounds against human cytomegalovirus and herpes simplex virus. , 1990, Journal of virological methods.

[30]  I. Rosenberg,et al.  Acyclic Nucleotide Analogues. Part 2. Synthesis of Potential Prodrugs and Metabolites of 9-(S)-(3-Hydroxy-2-phosphonylmethoxypropyl)adenine. , 1988 .

[31]  E. De Clercq,et al.  Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. , 1987, Antiviral research.

[32]  W. Setzer,et al.  The question of chair-twist equilibria for the phosphate rings of nucleoside cyclic 3',5'-monophosphates. Proton NMR and x-ray crystallographic study of the diastereomers of thymidine phenyl cyclic 3',5'-monophosphate , 1987 .

[33]  S. Krawczyk,et al.  Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus , 1987, Antimicrobial Agents and Chemotherapy.

[34]  A. Holý,et al.  Synthesis of potential prodrugs and metabolites of 9-( S )-(3-hydroxy-2-phosphonylmethoxypropyl)adenine , 1987 .

[35]  D. Gorenstein,et al.  Stereoelectronic Effects on the Conformation and Kinetics of Nucleophilic : Displacement reactions in epimeric six-membered ring phosphonate diesters , 1987 .

[36]  J. Balzarini,et al.  A novel selective broad-spectrum anti-DNA virus agent , 1986, Nature.

[37]  S. Kuwata,et al.  Studies of Unusual Amino Acids and Their Peptides. XVII. The Synthesis of Peptides Containing N-Carboxymethyl Amino Acids. II , 1985 .

[38]  D. Gorenstein,et al.  Stereoelectronic effects in the reactions of epimeric 2-aryloxy-2-oxy-1,3,2-dioxaphosphorinanes and oxazaphosphorinanes , 1980 .